Tim Clackson News Today

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024...

Theseus Pharmaceuticals has announced that the development of THE-630 as a potential therapeutic option for patients with gastrointestinal stromal tumor has been terminated, and enrollment to the ongoing phase 1/2 trial evaluating the agent’s safety and efficacy in this population has been discontinued.

-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a...

-- THE-630 demonstrates encouraging safety profile through Cohort 6 , supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both... | May 25, 2023

-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed...

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the...

GuruFocus Article or News written by PRNewswire and the topic is about: